Oncocyte Reports Second Quarter 2022 Financial Results
August 10, 2022 16:05 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Participate at Upcoming Investor Conferences
August 03, 2022 16:01 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022
August 01, 2022 05:00 ET
|
Oncocyte Corporation
IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Announce Second Quarter 2022 Financial Results
July 27, 2022 16:01 ET
|
Oncocyte Corporation
IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business
July 13, 2022 08:00 ET
|
Oncocyte Corporation
Oncocyte enters $2B US transplant monitoring market with newly branded VitaGraft™ patented dd-cfDNA technology in two indications, Kidney and Liver Oncocyte initiates IVD Kit Development Process with...
Oncocyte Presents DetermaIO™ Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022
July 06, 2022 08:00 ET
|
Oncocyte Corporation
Researchers conducted exploratory analysis to find an optimized IO score after validation of original established endpoint was presented at the 2022 ASCO Annual Meeting DetermaIO may help to...
Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice
June 22, 2022 08:00 ET
|
Oncocyte Corporation
IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), is a precision diagnostics company with the mission to improve patient outcomes by providing personalized...
Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test’s Potential to Expand the Clinical Use of Immunotherapy
May 26, 2022 17:00 ET
|
Oncocyte Corporation
DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need ...
Oncocyte Reports First Quarter 2022 Financial Results
May 11, 2022 16:05 ET
|
Oncocyte Corporation
IRVINE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test
May 05, 2022 08:00 ET
|
Oncocyte Corporation
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...